Literature DB >> 7345884

Effect of a new vasodilator, pinacidil (P 1134), on potassium, noradrenaline and serotonin induced contractions in rabbit vascular tissues.

C K Nielsen, E Arrigoni-Martelli.   

Abstract

Ring preparations of rabbit aorta were contracted by potassium (127 mM). Pinacidil (P 1134), a new vasodilator ( 2.3 x 10(-5) M), the calcium antagonists verapamil (3.4 x 10(-7) M), nifedipine (3.4 x 10(-9) M) and hydralazine (1.9 x 10(-4) M) relaxed the preparation by 50%. 50% relaxation of noradrenaline-contracted tissues was obtained with pinacidil, 6.8 x 10(-5) M, verapamil, 2.4 x 10(-3) M. At 2 x 10(-7) M concentration nifedipine was almost inactive. In ring preparations of rabbit aorta exposed to calcium-free medium and then depolarized with potassium (127 mM), pinacidil, 5 x 10(-5) M and nifedipine, 10(-8) M significantly inhibited the contractions by cumulative addition of calcium. Hydralazine, 10(-3) M had no effect. Noradrenaline-induced contractions in calcium-free medium or in presence of increasing amounts of calcium were significantly inhibited by nifedipine, 10(-8) M and hydralazine, 10(-3) M. Pinacidil, 10(-4) M had no effect. Pinacidil, 1.3 x 10(-5) M and verapamil, 2.0 x 10(-5) M inhibited by 50% the serotonin-induced increase of perfusion pressure of isolated rabbit ear artery. The noradrenaline effect in this preparation were 50% inhibited by pinacidil, 2.4 x 10(-4) M and by verapamil, 8.8 x 10(-5) M. Hydralazine, 10(-3) M exerted minor inhibitory effect. It is suggested that interference with calcium influx contributes to the vasodilator activity of pinacidil.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7345884     DOI: 10.1111/j.1600-0773.1981.tb00927.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  12 in total

Review 1.  Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  H A Friedel; R N Brogden
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

Review 2.  Pinacidil. Preclinical investigations.

Authors:  I Ahnfelt-Rønne
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 3.  Smooth muscle K+ channel openers; their pharmacology and clinical potential.

Authors:  A H Weston
Journal:  Pflugers Arch       Date:  1989       Impact factor: 3.657

4.  Evidence that pinacidil may promote the opening of ATP-sensitive K+ channels yet inhibit the opening of Ca2(+)-activated K+ channels in K(+)-contracted canine mesenteric artery.

Authors:  K Masuzawa; T Matsuda; M Asano
Journal:  Br J Pharmacol       Date:  1990-05       Impact factor: 8.739

5.  Pharmacodynamic model of the haemodynamic effects of pinacidil in normotensive volunteers.

Authors:  P Girard; J L Saumet; F Dubois; J P Boissel
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Evidence that the mechanism of the inhibitory action of pinacidil in rat and guinea-pig smooth muscle differs from that of glyceryl trinitrate.

Authors:  K M Bray; D T Newgreen; R C Small; J S Southerton; S G Taylor; S W Weir; A H Weston
Journal:  Br J Pharmacol       Date:  1987-06       Impact factor: 8.739

7.  Effects of putative activators of K+ channels in mouse pancreatic beta-cells.

Authors:  M G Garrino; T D Plant; J C Henquin
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

8.  Acute haemodynamic effects of pinacidil in man.

Authors:  D P Nicholls; J G Murtagh; M E Scott; P Morton; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

9.  Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.

Authors:  J W Ward; A McBurney; P R Farrow; P Sharp
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  In vitro studies on the mode of action of pinacidil.

Authors:  A H Weston; K M Bray; S Duty; A D McHarg; D T Newgreen; J S Southerton
Journal:  Drugs       Date:  1988       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.